Rathod Reena J, Sukumaran Reghu K, Kedia Neelam, Kumar Jeevan, Nair Reena, Chandy Mammen, Gandikota Lakshmikanth, Radhakrishnan Vivek Sulekha
Cell and Gene Therapy Division, Intas Pharmaceuticals, Ahmedabad, Gujarat, India.
Hematology Oncology and HCT, Tata Medical Center, Kolkata, West Bengal, India.
Indian J Cancer. 2024 Apr 1;61(2):204-214. doi: 10.4103/ijc.ijc_433_21. Epub 2024 Aug 6.
Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.
利用自身免疫系统治疗癌症一直是癌症生物学和治疗学中一个活跃的研究领域。细胞免疫疗法中的一个此类机会是过继性细胞转移。随着CAR-T疗法最近获批用于癌症治疗，一种全新的癌症治疗模式已然开启，为复发/难治性癌症患者带来了一线希望。尽管临床结果令人鼓舞，但该疗法仍处于早期阶段，由于成本高昂和后勤保障方面的挑战，大多数患者仍无法使用。在印度，这些疗法无法获得，经济挑战和庞大人口进一步加剧了这一问题。在本综述中，我们将讨论T细胞免疫疗法的各个方面，特别关注印度背景下的CAR-T疗法。我们将探讨CAR-T细胞疗法的基础科学方面、作用机制、生产制造、临床方面和商业方面，以及其在全球和印度的未来发展。
